CKD market expected to reach $10.9bn across the 7MM by 2035
The chronic kidney disease (CKD) market is poised to grow at a compound annual growth rate (CAGR) of 9.8% from…
Analyst Comment
Intismeran autogene a turning point for cancer vaccines
Reformed pharmaceutical regulation across India’s drug landscape
Updated UK guidance for finerenone introduces new treatment for HF patients
Repligen’s deal for BioLife Solutions indicates shift to manufacturing integration
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
What will health and social care look like under Andy Burnham?
European drug manufacturers under threat from proposed US supply chain bill
